Michael Hogan

Michael Hogan is reported to be a member of the Advisory Council for Columbia University’s TeenScreen Program (see Pharmaceutical Industry, PR and Mental Health Screening where Laurie Flynn serves as Director. He is also a member of the National Association of State Mental Health Program Directors (NASMHPD), past president of both NASMHPD and the NASMHPD Research Institute (NRI) (and more recently on the NRI Board of Directors) and an Advisory Board member of Janssen Pharmaceuticals Mental Health Issues Today (MHIT), a journal published by Parexel Medical Marketing, which receives funds from drug companies to run "advisory panels" on their behalf. It should also be noted that the NASHPD is heavily supported through 'educational grants' by Janssen Pharmaceuticals and Eli Lilly.

In 2004, Hogan is describes as the chair of President Bush’s New Freedom Commission on Mental Illness by Eli Lilly who awarded him a 'Lifetime Achievement Award' for his 'stewardship and advocacy in the implementation of the New Freedom Commission Report’s recommendations, and his lifelong commitment to enhancing services for people with mental illnesses'.

Hogan and Laurie Flynn were involved in the Expert Consensus Guideline Series: Treatment of Schizophrenia 1999 an initiative aiming at establishing uniform medication guidelines for schizophrenia. It is reported that this was an initiative 'supported exclusively by 6 pharmaceutical companies: Eli Lilly and Company, Janssen Pharmaceutica Inc., Novartis Pharmaceuticals Corporation, Ortho-McNeil Pharmaceutical, Pfizer Inc. and Zeneca Pharmaceuticals' (now known as AstraZeneca).